Zobrazeno 1 - 10
of 32
pro vyhledávání: '"J. J. Van Veen"'
Autor:
Oliver Chapman, William Lester, Debra Ellis, K. Douglas, John-Paul Westwood, Sylvia Benjamin, Tanya Cranfield, Chiara Vendramin, Katy Langley, Tina T. Biss, J. J. van Veen, Karen Vanhoorelbeke, Lynn Manson, Ferras Alwan, Mari Thomas, Nichola Cooper, Quentin A. Hill, Steve Austin, Tina Dutt, Richard Gooding, Amanda Clark, Marie Scully, Vickie McDonald, Henry G. Watson, William Thomas, Keith Sibson
Publikováno v:
Blood. 130:466-471
Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by antibodies against ADAMTS13. From the United Kingdom TTP registry, we undertook a prospective study investigating the impact of the presenting anti-ADA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be8265b94a5d31ebfaf925ab8ad0cab1
https://doi.org/10.1182/blood-2016-12-758656
https://doi.org/10.1182/blood-2016-12-758656
Publikováno v:
International journal of laboratory hematology. 40(4)
Introduction Argatroban is a direct thrombin inhibitor used as an anticoagulant for patients who have Heparin induced thrombocytopenia. Quantification can be performed using a dilute thrombin time or anti-iia assay. Our preferred method is Hemoclot T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::669b01716b57abfc104d9cc80bd7b197
https://pubmed.ncbi.nlm.nih.gov/29707901
https://pubmed.ncbi.nlm.nih.gov/29707901
Publikováno v:
International Journal of Laboratory Hematology. 37:834-843
SummaryBackground Argatroban is licensed for patients with heparin-induced thrombocytopenia and monitoring is conventionally by activated partial thromboplastin time (APTT) ratio with a target of 1.5–3.0 and not exceeding 100 s. The APTT may be inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff5b5e6517128ca990d2bc4b657dfef
https://doi.org/10.1111/ijlh.12414
https://doi.org/10.1111/ijlh.12414
Publikováno v:
Haemophilia. 20:587-592
Summary Major surgery in persons with haemophilia A and inhibitors is increasingly being performed. Both recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (APCC) are used to cover surgery but it remains unclear w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fde348820e8870e4095b860f46bffcb3
https://doi.org/10.1111/hae.12365
https://doi.org/10.1111/hae.12365
Publikováno v:
Thrombosis research. 147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3011f80763b5ab7d2c0d7ac38c45cf62
https://pubmed.ncbi.nlm.nih.gov/27669125
https://pubmed.ncbi.nlm.nih.gov/27669125
Autor:
Steve Kitchen, J. M. Smith, Anita M. Woolley, Michael Makris, Annette E. Bowyer, Rhona Maclean, K. K. Hampton, J. J. Van Veen
Publikováno v:
International Journal of Laboratory Hematology. 33:212-218
Summary Introduction: An isolated prolongation to the activated partial thromboplastin time (APTT) can be caused by the presence of the lupus anticoagulant or an intrinsic or contact factor deficiency, of which only deficiencies of factors VIII, IX o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc24d8be44765a71eb6640bf4561c3b1
https://doi.org/10.1111/j.1751-553x.2010.01266.x
https://doi.org/10.1111/j.1751-553x.2010.01266.x
Publikováno v:
International Journal of Clinical Practice. 64:1468-1471
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3aae1d7cfc0d4b33acce207931c93fa
https://doi.org/10.1111/j.1742-1241.2010.02413.x
https://doi.org/10.1111/j.1742-1241.2010.02413.x
Publikováno v:
British Journal of Haematology. 142:889-903
Thrombin is the central enzyme in the coagulation cascade. Estimation of an individual's potential to generate thrombin may correlate more closely with a hyper- or hypo-coagulable phenotype, compared to traditional coagulation tests. The possible cor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62925f2a467d6e4c3df04705d1a6e784
https://doi.org/10.1111/j.1365-2141.2008.07267.x
https://doi.org/10.1111/j.1365-2141.2008.07267.x
Autor:
Michael Makris, Thynn Thynn Yee, Krista Fischer, Anja Griffioen, Evelien P. Mauser-Bunschoten, Dirk Posthouwer, J. J. Van Veen
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:1624-1629
Background: Hepatitis C is a major co-morbidity in patients with hemophilia. However, there is little information on the efficacy of antiviral therapy and long-term follow-up after treatment. Objectives: To assess the effect of interferon-based (IFN-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e477dc52ec9ef70dd33e06346d8469
https://doi.org/10.1111/j.1538-7836.2007.02619.x
https://doi.org/10.1111/j.1538-7836.2007.02619.x